← All Monopar Therapeutics filings

Monopar Therapeutics Schedule 13D activist filings

Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.

NASDAQ
MNPR
Monopar Therapeutics
SCHEDULE: Tactic Pharma Exits Monopar Therapeutics Stake
Tactic Pharma LLC and its principals have ceased to be beneficial owners of more than five percent of Monopar Therapeutics common stock following a pro rata distribution to its members.
NASDAQ
MNPR
Monopar Therapeutics
SCHEDULE: Monopar Therapeutics Buys Back Shares from Tactic Pharma
Monopar Therapeutics is repurchasing 550,229 shares of its common stock from Tactic Pharma LLC at $63.6098 per share, contingent on a concurrent public offering.
NASDAQ
MNPR
Monopar Therapeutics
SCHEDULE 13D/A: Major Shareholders of Gem Pharmaceuticals Agree to Lock-Up on Distributed Shares
Key shareholders of Gem Pharmaceuticals LLC, including Monopar Therapeutics and individuals Diane Hendricks and Karl Leo, have entered into a lock-up agreement restricting the sale of their recently distributed common stock until December 31, 2025.